These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 16062099)

  • 21. Kinetic-dynamic monitoring of levetiracetam effects in patients with Parkinson disease and levodopa-induced dyskinesias.
    Contin M; Martinelli P; Albani F; Scaglione C; Avoni P; Rizzo G; Baruzzi A
    Clin Neuropharmacol; 2007; 30(2):122-4. PubMed ID: 17414945
    [No Abstract]   [Full Text] [Related]  

  • 22. Trimetazidine induces parkinsonism, gait disorders and tremor.
    Martí Massó JF; Martí I; Carrera N; Poza JJ; López de Munain A
    Therapie; 2005; 60(4):419-22. PubMed ID: 16268443
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study.
    Woods SW; Saksa JR; Baker CB; Cohen SJ; Tek C
    J Clin Psychiatry; 2008 Apr; 69(4):546-54. PubMed ID: 18312060
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug-induced movement disorders.
    Jiménez-Jiménez FJ; García-Ruiz PJ; Molina JA
    Drug Saf; 1997 Mar; 16(3):180-204. PubMed ID: 9098656
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An open-label pilot study of levetiracetam for essential tremor.
    Ondo WG; Jimenez JE; Vuong KD; Jankovic J
    Clin Neuropharmacol; 2004; 27(6):274-7. PubMed ID: 15613931
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Parkinsonism during lithium use].
    Walrave TR; Bulens C
    Tijdschr Psychiatr; 2009; 51(2):123-7. PubMed ID: 19194854
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Levetiracetam for the treatment of co-occurring alcohol dependence and anxiety: case series and review.
    Mariani JJ; Levin FR
    Am J Drug Alcohol Abuse; 2008; 34(6):683-91. PubMed ID: 18850500
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Amisulpride in Huntington's disease].
    Saft C; Andrich J; Kraus PH; Przuntek H
    Psychiatr Prax; 2005 Oct; 32(7):363-6. PubMed ID: 16220421
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The "neuroleptic" antipsychotic drugs. 2. Neurologic side effects.
    Baldessarini RJ
    Postgrad Med; 1979 Apr; 65(4):123-8. PubMed ID: 34142
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Levetiracetam as adjunctive antiepileptic therapy for patients with tuberous sclerosis complex: a retrospective open-label trial.
    Collins JJ; Tudor C; Leonard JM; Chuck G; Franz DN
    J Child Neurol; 2006 Jan; 21(1):53-7. PubMed ID: 16551454
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alcohol-triggered-neuroleptic-induced tremor, rigidity and dystonia.
    Freed E
    Med J Aust; 1981 Jul; 2(1):44-5. PubMed ID: 6116168
    [No Abstract]   [Full Text] [Related]  

  • 32. Piracetam and levetiracetam: close structural similarities but different pharmacological and clinical profiles.
    Genton P; Van Vleymen B
    Epileptic Disord; 2000 Jun; 2(2):99-105. PubMed ID: 10954241
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In reference to Usery JB et al. (J Neuro-oncol. 2010 Feb 10).
    Maschio M; Dinapoli L; Jandolo B
    J Neurooncol; 2010 Dec; 100(3):491-2. PubMed ID: 20461444
    [No Abstract]   [Full Text] [Related]  

  • 34. Correspondence on ''the unrecognized epilepsy spectrum: the effects of levetiracetam on neuropsychological functioning in relation to subclinical spike production''.
    Duane DD
    J Child Neurol; 2009 Dec; 24(12):1578; author reply 1579. PubMed ID: 19955348
    [No Abstract]   [Full Text] [Related]  

  • 35. Levetiracetam for the treatment of alcohol withdrawal syndrome: an open-label pilot trial.
    Krebs M; Leopold K; Richter C; Kienast T; Hinzpeter A; Heinz A; Schaefer M
    J Clin Psychopharmacol; 2006 Jun; 26(3):347-9. PubMed ID: 16702910
    [No Abstract]   [Full Text] [Related]  

  • 36. Pilot efficacy and tolerability: a randomized, placebo-controlled trial of levetiracetam for essential tremor.
    Handforth A; Martin FC
    Mov Disord; 2004 Oct; 19(10):1215-21. PubMed ID: 15390011
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Levetiracetam in the treatment of paroxysmal kinesiogenic choreoathetosis.
    Chatterjee A; Louis ED; Frucht S
    Mov Disord; 2002 May; 17(3):614-5. PubMed ID: 12112221
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment with levetiracetam improves cognition in a ketamine rat model of schizophrenia.
    Koh MT; Shao Y; Rosenzweig-Lipson S; Gallagher M
    Schizophr Res; 2018 Mar; 193():119-125. PubMed ID: 28634087
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Levetiracetam is not effective for essential tremor.
    Elble RJ; Lyons KE; Pahwa R
    Clin Neuropharmacol; 2007; 30(6):350-6. PubMed ID: 18090460
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Levetiracetam in autistic children: an open-label study.
    Rugino TA; Samsock TC
    J Dev Behav Pediatr; 2002 Aug; 23(4):225-30. PubMed ID: 12177568
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.